Well, in the case of a cancer that has developed h
Post# of 148155
So, in cases where Keytruda was once effective against a cancer, but over time, has become less and less effective as the tumor became more and more resistant to the PD-1 therapy, then, with the addition of leronlimab, the CCR5 blockade would disable the tumor's capacity to evade the PD-1 blocker's mechanism of action.
Therefore, the addition of leronlimab would restore Keytruda as an effective treatment against that specific cancer.
My Rationale Presented Here